<DOC>
	<DOCNO>NCT03053076</DOCNO>
	<brief_summary>To study safety efficacy Autologous Umbilical Cord Blood Mononuclear Cells transfusion clinical outcome preterm infant</brief_summary>
	<brief_title>Safety Efficacy Autologous Umbilical Cord Blood Mononuclear Cells Transfusion Neonates</brief_title>
	<detailed_description>This Phase 1 clinical trial constitutes two time point cohorts 100 participant per cohort receive intravenous dos Autologous Umbilical Cord Blood Mononuclear Cells -- 25 million cells/kg , 48 hour birth . And placebo 0.9 % sodium chloride.The investigator proceed group period . 1 . Demographic Data Baseline Characteristics Studied Groups collect : - Gestational age ( week ) - Birth weight ( g ) - gender - Cesarean section delivery - Antenatal steroid - Prolonged rupture membrane - Multiple pregnancy - APGAR score 5 minute - Thrombocytopenia intervention - CRP intervention ( mg/L ) - TNF-α ( tumor necrosis factor α ) intervention ( pg/mL ) 2 . Assessment clinical condition course measurement arterial blood pressure , heart respiratory rate skin temperature record continuously 3 . Autologous cord blood mononuclear cell dose 25 million cells/kg ，the infusion speed 4ml/kg/h， 8-12h，and volume 0.9 % sodium chloride placebo . 4 . The following monitor 3、7、14、21 day birth : - mortality , incidence sepsis , neonatal respiratory distress syndrome ( NRDS ) , bronchopulmonary dysplasia ( BPD ) , retinopathy prematurity ( ROP ) , necrotising enterocolitis ( NEC ) , intraventricular haemorrhage ( IVH ) , Hypoxic Ischemic Encephalopathy ( HIE ) , anaemia , thrombocytopenia , neutrophil , TBNK cell subgroup , hospital discharge . 5 . Long-term follow : 1m , 3m , 6m,1y : neurodevelopment [ Bayley Scales Infant ] , asthma , anemia physique growth .</detailed_description>
	<mesh_term>Perinatal Death</mesh_term>
	<criteria>Twentyeight week thirtyseven week Preterm infant major congenital malformation , chromosomal anomaly , inborn error metabolism clinical laboratory evidence congenital infection</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>37 Weeks</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cord blood mononuclear cell</keyword>
	<keyword>safety</keyword>
	<keyword>effect</keyword>
	<keyword>neonate</keyword>
</DOC>